TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions
Clinical trial NCT01052883 · COMPLETED
Trial details
- NCT number
- NCT01052883
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-03-01
- Primary completion
- 2010-06-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.